55 related articles for article (PubMed ID: 26319365)
21. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
23. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
25. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
26. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Groesser L; Herschberger E; Landthaler M; Hafner C
Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
28. The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.
Purdie KJ; Proby CM; Rizvi H; Griffin H; Doorbar J; Sommerlad M; Feltkamp MC; der Meijden EV; Inman GJ; South AP; Leigh IM; Harwood CA
Front Microbiol; 2018; 9():1806. PubMed ID: 30154763
[No Abstract] [Full Text] [Related]
29. Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review.
Selmer J; Skov T; Spelman L; Weedon D
Histopathology; 2016 Oct; 69(4):535-41. PubMed ID: 27323251
[TBL] [Abstract][Full Text] [Related]
30. Rapidly developed BRAF inhibitor-induced verrucous keratosis.
Nakamura Y; Mori T; Takae Y; Tsutsumida A; Takahashi A; Namikawa K; Hirai I; Yamazaki N
J Dermatol; 2017 Nov; 44(11):e274-e275. PubMed ID: 28734005
[No Abstract] [Full Text] [Related]
31. BRAF inhibitor induced verrucal keratosis.
Anforth R; Fernandez-Penas P
Am J Dermatopathol; 2014 Feb; 36(2):192. PubMed ID: 23435364
[No Abstract] [Full Text] [Related]
32. Genetic alterations in seborrheic keratoses.
Heidenreich B; Denisova E; Rachakonda S; Sanmartin O; Dereani T; Hosen I; Nagore E; Kumar R
Oncotarget; 2017 May; 8(22):36639-36649. PubMed ID: 28410231
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma.
Lowry WS; Atkinson RJ
Br J Dermatol; 1993 Jun; 128(6):708. PubMed ID: 8338763
[No Abstract] [Full Text] [Related]
34. Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity.
da Fonseca LG; Fuster-Anglada C; Carrera C; Millán C; Samper E; Sapena V; Díaz-González Á; Sanduzzi-Zamparelli M; Leal C; Forner A; Bruix J; Reig M; Boix L; Díaz A
Oncotarget; 2021 Mar; 12(5):440-449. PubMed ID: 33747359
[TBL] [Abstract][Full Text] [Related]
35. Chromosome studies in pitch warts.
Everal JD; Hansteen IL; Lawler SD
Br J Dermatol; 1967 May; 79(5):271-7. PubMed ID: 4225901
[No Abstract] [Full Text] [Related]
36. Erratum to: Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2016 Feb; 19(1):113. PubMed ID: 26450712
[No Abstract] [Full Text] [Related]
37. BRAF Mutational Intertumoral Discrepancies: Think About Technical Limitations Instead of Mutational Heterogeneity.
Uguen A; Uguen M
Am J Dermatopathol; 2017 Jan; 39(1):66. PubMed ID: 27097343
[No Abstract] [Full Text] [Related]
38. The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma.
Thompson EL; Hu JJ; Niedernhofer LJ
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066966
[No Abstract] [Full Text] [Related]
39. Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.
Corchado-Cobos R; García-Sancha N; González-Sarmiento R; Pérez-Losada J; Cañueto J
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331425
[TBL] [Abstract][Full Text] [Related]
40. Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.
Emami NC; Leong L; Wan E; Van Blarigan EL; Cooperberg MR; Tenggara I; Carroll PR; Chan JM; Witte JS; Simko JP
Prostate; 2017 Mar; 77(4):425-434. PubMed ID: 27900799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
